The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

Alan Kaplan; Heath Heatley; John Townend; Derek Skinner; Victoria Carter; Richard Hubbard; Tan Tze Lee; Mariko Siyue Koh; David Price

doi:10.1007/s12325-025-03175-x

The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

Alan Kaplan
, Heath Heatley
, John Townend
, Derek Skinner
, Victoria Carter
, Richard Hubbard
, Tan Tze Lee
, Mariko Siyue Koh
, David Price^*

^*Corresponding author for this work

Research output: Journal Publication › Article › peer-review

11 Citations (Scopus)

Abstract

To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90–2.36) and OAC (OR 2.10, 95%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.

Original language	English
Article number	e30812
Pages (from-to)	2950-2956
Number of pages	7
Journal	Advances in Therapy
Volume	42
Issue number	6
DOIs	https://doi.org/10.1007/s12325-025-03175-x
Publication status	Published - Jun 2025
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Free Keywords

Asthma
Asthma outcomes
GLP1s
Obesity

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1007/s12325-025-03175-x

Cite this

@article{23a03d73dcaa4b709668824f3347db04,

title = "The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity",

abstract = "To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95\% CI 1.90–2.36) and OAC (OR 2.10, 95\%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.",

keywords = "Asthma, Asthma outcomes, GLP1s, Obesity",

author = "Alan Kaplan and Heath Heatley and John Townend and Derek Skinner and Victoria Carter and Richard Hubbard and Lee, \{Tan Tze\} and Koh, \{Mariko Siyue\} and David Price",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = jun,

doi = "10.1007/s12325-025-03175-x",

language = "English",

volume = "42",

pages = "2950--2956",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Adis",

number = "6",

}

TY - JOUR

T1 - The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

AU - Kaplan, Alan

AU - Heatley, Heath

AU - Townend, John

AU - Skinner, Derek

AU - Carter, Victoria

AU - Hubbard, Richard

AU - Lee, Tan Tze

AU - Koh, Mariko Siyue

AU - Price, David

N1 - Publisher Copyright: © The Author(s) 2025.

PY - 2025/6

Y1 - 2025/6

N2 - To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90–2.36) and OAC (OR 2.10, 95%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.

AB - To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90–2.36) and OAC (OR 2.10, 95%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.

KW - Asthma

KW - Asthma outcomes

KW - GLP1s

KW - Obesity

UR - https://www.scopus.com/pages/publications/105002171129

U2 - 10.1007/s12325-025-03175-x

DO - 10.1007/s12325-025-03175-x

M3 - Article

C2 - 40198520

AN - SCOPUS:105002171129

SN - 0741-238X

VL - 42

SP - 2950

EP - 2956

JO - Advances in Therapy

JF - Advances in Therapy

IS - 6

M1 - e30812

ER -

The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

Abstract

UN SDGs

Free Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this